NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.20 -0.12 (-1.90 %) (As of 12/11/2019 04:00 PM ET) Add Compare Today's Range$5.97Now: $6.20▼$6.4150-Day Range$3.67MA: $4.73▼$6.8452-Week Range$3.42Now: $6.20▼$9.74Volume75,200 shsAverage Volume94,709 shsMarket Capitalization$130.31 millionP/E RatioN/ADividend YieldN/ABeta2.9 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLMD Previous Symbol CUSIPN/A CIK1595353 Webhttp://www.galmedpharma.com/ Phone972-3693-8448Debt Debt-to-Equity Ratio0.01 Current Ratio22.78 Quick Ratio22.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.04 million Price / Sales63.88 Cash FlowN/A Price / Cash FlowN/A Book Value$4.18 per share Price / Book1.48Profitability EPS (Most Recent Fiscal Year)($0.54) Net Income$-9,860,000.00 Net MarginsN/A Return on Equity-19.16% Return on Assets-18.42%Miscellaneous Employees17 Outstanding Shares21,018,000Market Cap$130.31 million Next Earnings Date3/11/2020 (Estimated) OptionableOptionable Receive GLMD News and Ratings via Email Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GLMD Rates by TradingView Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions What is Galmed Pharmaceuticals' stock symbol? Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD." How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.11. View Galmed Pharmaceuticals' Earnings History. When is Galmed Pharmaceuticals' next earnings date? Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Galmed Pharmaceuticals. What price target have analysts set for GLMD? 6 brokerages have issued twelve-month target prices for Galmed Pharmaceuticals' shares. Their forecasts range from $10.00 to $59.00. On average, they expect Galmed Pharmaceuticals' share price to reach $30.00 in the next year. This suggests a possible upside of 383.9% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals. What is the consensus analysts' recommendation for Galmed Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals. What are Wall Street analysts saying about Galmed Pharmaceuticals stock? Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock: 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (11/12/2019) 2. Maxim Group analysts commented, "Galmed reported 2Q19 with a net loss of ($4.2M) and ended the period with $83.6M in cash." (8/6/2019) 3. HC Wainwright analysts commented, "We maintain our Buy rating of ATEC and raise our 12-month price target to $6.00 per share, up from $4.00. We derive our price target based on: (1) an EV-to-sales multiple analysis assuming 10% discount rate and using a 3.0x multiple on projected 2027 sales of $455M; and (2) a discounted cash flow analysis using the projected free cash flow to the firm through 2027 and assuming a 10% discount rate and a 3% terminal growth rate. Using the average of the two methods, we arrive at a 12-month price target of $5.80 per share, which we round to $6.00." (8/6/2019) Has Galmed Pharmaceuticals been receiving favorable news coverage? News coverage about GLMD stock has been trending very negative recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Galmed Pharmaceuticals. Are investors shorting Galmed Pharmaceuticals? Galmed Pharmaceuticals saw a drop in short interest during the month of November. As of November 29th, there was short interest totalling 438,700 shares, a drop of 9.4% from the November 14th total of 484,000 shares. Based on an average daily trading volume, of 109,200 shares, the short-interest ratio is currently 4.0 days. Approximately 3.0% of the shares of the stock are sold short. View Galmed Pharmaceuticals' Current Options Chain. Who are some of Galmed Pharmaceuticals' key competitors? Some companies that are related to Galmed Pharmaceuticals include Crinetics Pharmaceuticals (CRNX), RAPT Therapeutics (RAPT), Lexicon Pharmaceuticals (LXRX), Prothena (PRTA), Morphic (MORF), Stemline Therapeutics (STML), Emisphere Technologies (EMIS), Frequency Therapeutics (FREQ), MacroGenics (MGNX), Ardelyx (ARDX), Akorn (AKRX), Catalyst Pharmaceuticals (CPRX), Organogenesis (ORGO), Sinovac Biotech (SVA) and ProQR Therapeutics (PRQR). What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Rite Aid (RAD), Exelixis (EXEL), Viking Therapeutics (VKTX), Verastem (VSTM), Immunomedics (IMMU), Micron Technology (MU), Conatus Pharmaceuticals (CNAT), Corbus Pharmaceuticals (CRBP) and NVIDIA (NVDA). Who are Galmed Pharmaceuticals' key executives? Galmed Pharmaceuticals' management team includes the folowing people: Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)Mr. Yohai Stenzler, CFO & Controller (Age 36)Mr. Guy Nehemya, Chief Operating Officer (Age 34)Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)Dr. Tali Gorfine, Chief Medical Officer (Age 49) Who are Galmed Pharmaceuticals' major shareholders? Galmed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Ibex Investors LLC (4.54%), Phoenix Holdings Ltd. (0.12%) and Stifel Financial Corp (0.06%). Which major investors are selling Galmed Pharmaceuticals stock? GLMD stock was sold by a variety of institutional investors in the last quarter, including Stifel Financial Corp. Which major investors are buying Galmed Pharmaceuticals stock? GLMD stock was purchased by a variety of institutional investors in the last quarter, including Ibex Investors LLC and Phoenix Holdings Ltd.. How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Galmed Pharmaceuticals' stock price today? One share of GLMD stock can currently be purchased for approximately $6.20. How big of a company is Galmed Pharmaceuticals? Galmed Pharmaceuticals has a market capitalization of $130.31 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.View Additional Information About Galmed Pharmaceuticals. What is Galmed Pharmaceuticals' official website? The official website for Galmed Pharmaceuticals is http://www.galmedpharma.com/. How can I contact Galmed Pharmaceuticals? Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448. MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 391 (Vote Outperform)Underperform Votes: 207 (Vote Underperform)Total Votes: 598MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/11/2019 by MarketBeat.com StaffFeatured Article: Why investors pay attention to retained earnings
